Leukemia

Excellent MDS session chaired by @beatalleukemia featuring @MikkaelSekeres @DrPinkalDesai & others - the topics included clinical trial endpoints, HMA-exposed AML, CCUS, and IRAK4 inhibitors! #mdssm #DAVABermudaHeme (@Anand_88_Patel)

Very cool to hear @beatalleukemia’s fascinating CCUS work at @DAVAOnc Bermuda: Based on compelling data that inflammation drives CCUS progression and that IL-1B blockade blocks it, they’ll be looking at this in an RCT with progression to MDS as endpoint. Exciting concept! https://t.co/uFZXu4mrqa (@RahulBanerjeeMD)

Check out our interview with @wwierda of @MDAndersonNews, who outlines disease characteristics impacting treatment decisions in CLL, including the role of TP53, del(17p), and IgHV mutations: 👉 https://t.co/D50LqhCHtd 👈 @EHA_Hematology #EHA2023 #LeuSM #CLLsm #HemOnc (@VJHemOnc)

#ICYMI the July issue— A Phase Ib/II Study of Ivosidenib with #Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies, by @CLachowiez et al. https://t.co/PDtssjLQyN @OHSUSOM #leuSM (@BCD_AACR)

Learn about new #BTKinhibitor options, antibodies, BCL2 inhibitors, & cellular therapy for #CLL treatment from @DrMDavids @AdamKittai @wwierda & Dr. Lamanna! This activity from #ASCO23 provides clear guidance & strategies for optimal treatment: https://t.co/YuFAL21ldw @PeerView (@CllSociety)

My brother has leukemia, and I want to ask for help (@lwbwant)

👉Challenging the Value of Minimal Residual Disease in Predicting Outcome of Patients With Chronic Lymphocytic Leukemia by Thomas Kipps @JCO_ASCO https://t.co/np2QeXw3Az (@SLentzsch)

🗣️:🇺🇲/👥: 👨‍⚕️🩸🦀 🤔 Peripheral flow cytometry for a possibility of firstly hairy cell leukemia and than marginal zone lymphoma. Bone marrow Asp&biopsy for BRAF mutation, and further differantiate possible causes. If one of them watch & wait might be a rational solution. (@Dr_MSU)

👉👉👉Congratulations to our superstar #PharmD Dr @CRausch_PharmD for being awarded #40Under40inCancer & to all awarded!! Also welcome @CRausch_PharmD to @Twitter as our newest friend & colleague to join #medtwitter !! #leusm #MPNSM #BPDCN | @Marxk @YLeyfman @ajperissinotti (@doctorpemm)

Are you current on modern therapeutics for patients with #AML? Watch Drs. @Daver_Leukemia, @beatalleukemia, Harry Erba, & Amir Fathi discuss the latest in this CME video, taken from our recent event at #ASCO23. Produced in partnership with @HealthTreeAML. https://t.co/XX5nNy0fKz (@PeerView)

Dr. @aditishasMD at @MDAndersonNews Leukemia giving an excellent talk on the role of STAT3 in AML! it is not everyday that a speaker shows you a pic of their own mitochondria 😲… that’s next level dedication. Sadly I wasn’t fast enough to take a pic of her mitochondria #leusm (@sanamloghavi)

Venetoclax helps to eliminate the adverse prognostic impact of splicing factor mutations in pts with newly diagnosed AML - @DrHKantarjian #cancer #leukemia #MDAndersoncancercenter #researchers #venetoclax #aml #oncology #drugs #oncodaily https://t.co/xblGnHD2vX (@oncodaily)

Glad to see our translational research for leukemia patients highlighted in the Luxembourgish press 👍@BloodJournal @LIH_Luxembourg (@TSI_lab_LIH)

🙌 Delighted to host Dr .@aditishasMD, world expert myeloid malignancies, from Albert Einstein NYC visiting us here at Leukemia Dept @MDAndersonNews for Leukemia Grand Rounds meeting hosted by Dr @garciamanero which will be tomorrow! @beatalleukemia @sanamloghavi #leusm #MDSsm (@doctorpemm)

2) .@tobyeyre82 discusses here more on #pharmacology, patient selection for #CAR_T, and sequencing of CAR T tx in the management of #CLL. Until recently, this approach was not as successful as it has been in #B_cell #leukemia and #lymphoma. (@onc_ce)

1) Welcome to a 🆕#accredited #tweetorial providing 0.5hr 🆓CE/CME like no other #MedEd #onctwitter resource! Returning expert author Toby Eyre @tobyeyre82, #CLL specialist @OUHospitals @UniofOxford in this program continues his discussion of #CAR_T tx for CLL. #FOAMed #CLLsm (@onc_ce)

Un programa fantástico! Un enorme placer encontrarme entre los ponentes de esta iniciativa, muchísimas gracias a @NidiaZa07175883 y @GomezDLeonMD por la organización! Como dice la Dra. Zapata, no os lo perdáis! #MDS #acuteleukemia (@monicahemato)

Out now in @JAMAOnc by Dr. Nirali Shah @NiraliShahMD & team: "Management of Down Syndrome–Associated Leukemias" - provides considerations for caring for pediatric & AYA patients with down syndrome who are at higher risk for developing #leukemia. Read here: https://t.co/wf1rYvhdGD (@NCI_CCR_PedOnc)

📣 #ESHAL2024 ABSTRACT & CLINICAL CASE SUBMISSION IS OPEN! Submit yours now ➡ https://t.co/L4J85vyKoY 🗓️ March 1-3, 2024 in Stockholm 🇸🇪 4th How to Diagnose & Treat #ACUTE #LEUKAEMIAS Chairs: @DombretHerve , @Gossenkoppele, Christoph Röllig, Wendy Stock #ESHCONFERENCES #leusm (@ESHaematology)

@CureLeukaemia @charliecraddock @act4patients (@PaulSherringto7)

First JAMA article was published last year - Myelodysplastic Syndromes https://t.co/mqqEDogZRP with @MikkaelSekeres @SylvesterCancer #MDSsm #leusm (@TaylorJ_MD)

@MDAndersonNews #Leukemia researchers identify the use of venetoclax helps to eliminate the adverse prognostic impact of splicing factor mutations in pts with newly diagnosed #AML | @BloodJournal https://t.co/J2sUGN9nVh #leusm (@DrHKantarjian)

#WhenOnService | Day One attending on Leukemia Inpatient Service 🙌 | #Grateful #Hope #endcancer 🙏🏾 to our wonderful @MDAndersonNews Leukemia team➡️best in the entire world 🌍!! #Leadership #MPNSM #BPDCN #leusm 👏🏽 @sanamloghavi @VivekSubbiah @Aiims1742 #teamworkmakesthedreamwork (@doctorpemm)

➡️ Check out our latest paper 📃 just out in @BloodJournal analyzing the outcomes of patients with Newly Dx AML having Splicing Factor gene mutations 🧬and the impact of Venetoclax based regimens 💊 @ CDDiNardo @DrHKantarjian @garciamanero @sanamloghavi @MDAndersonNews #leusm https://t.co/zDVTSmk4ci (@jayastuMD)

Three cheers to @MDAndersonNews Leukemia team! (@jayastuMD)

📢 In this trial, pirtobrutinib showed efficacy in patients with heavily pretreated CLL or SLL who had received a covalent BTK inhibitor @NEJM Read➡️https://t.co/me8JOkT0VG #MedTwitter @Daver_Leukemia @LeukemiaRF @LLSResearch @LYM_MM_CONNECT @lymphomahub @Lymphoma_Doc (@bloodmeded)

Thanks for your support, and let's work together with @CureLeukaemia with @GeoffThomasGTF and @charliecraddock for adults and children too (@rob_wynn_TdF)

@act4patients @CureLeukaemia @GeoffThomasGTF @Hayden1974 @GaryLineker @charliecraddock Absolutely, we’ve followed every stage (@PaulSherringto7)

It could be worse. You could be a prostate cancer doctor who did not board in Heme trying to answer questions about rare leukemias I have not nor will I ever treat. (@DSolit)

👉👉👉Welcome to @MDAndersonNews to our new superstar brilliant heme/onc fellow MD, Dr @HannahGoulart !! First rotation with Dr Q @Transplant_Doc & first clinic with Dr P @doctorpemm ➡️ a wonderful way to join fellowship #MindingYourPsAndQs #MPNSM #BPDCN #leusm #bmtsm #endcancer (@doctorpemm)

Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies | Leukemia ⁦@doctorpemm⁩ 👏🏻 https://t.co/91q2jEHP3V (@UsuarezMD)

Congrats to @mshadman for receiving an endowed chair for his work in #cll and lymphoma! (@UjjaniC)

📣 Leukemia expert Prithviraj Bose (@bose_prithviraj), MD, reveals groundbreaking news for #PV patients at the 2023 #ASCO Annual Meeting. 📲 Discover the latest advances in PV treatment with ruxolitinib: https://t.co/TnhdWmPvYl #MPNsm #MPNresearch #Ruxolitinib #AskPatients (@gmpnsf)

Excited to welcome our great friend, heme world expert & superb colleague Dr .@aditishasMD who will be joining us to give our Leukemia Grand Rounds this coming week! #leusm #MDSsm #MPNSM | @garciamanero @Amitvermamds @mkonople @sanamloghavi 🙌 (@doctorpemm)

I always enjoy reading a good MPN-AP/BP review! #mpnsm #leusm @RaajitRampal https://t.co/HDeUr9Ocb0 (@Anand_88_Patel)

Check out this Seminars and Tumor Board activity from #ASCO23 to hear the latest data on using modern therapeutics for patients with #AcuteMyeloidLeukemia, featuring Drs. @Daver_Leukemia, @beatalleukemia, Erba, & Fathi. Developed with @PeerView! https://t.co/z5R2uYRQro #AML (@HealthTreeAML)

Faggot cells Acute promyelocytic leukemia: hypergranular It's an oncological emergency: DIC Early death due to catastrophic bleeding is the biggest concern. Urgent initiation of ATRA and aggressive hemostatic support are crucial https://t.co/rZr8tW3qPb (@Pritampedhemonc)

Path finals, gross specimen identification station. Examiner: Please identify (points at a teratoma) Candidate: I don't know. Examiner: What's this? (points at hair) Candidate: Hair Examiner: So, what's the specimen likely to be? Candidate: 💡 Hairy cell leukaemia Examiner: 🤦🏽‍♂️ (@ashwinrajenesh)

Response rate to vemurafenib in refractory hairy cell leukemia was 96 to 100 percent; NEJM Tiacci et al, 2015 :) (@Dr_R_Kurzrock)

CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA WHO DEVELOPED THERAPY-RELATED ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME FOLLOWING AUTOLOGOUS CELL TRANSPLANTATION https://t.co/ZuGML7u2RJ @Fevzi_F_Yalniz @DQBMD @MDAndersonNews #bmtsm #leusm #mmsm (@Transplant_Doc)

👉👉👉Brilliant discussion 💡 catching up for a few moments with best of the best all-world leukemia colleagues at work today! @doctorpemm @TapKadia #MontalbanBravo @GhayasIssa | #BPDCN #MPNSM #leusm #CMMLsm #MeninInhibitors #endcancer | @sanamloghavi @Aiims1742 @VivekSubbiah (@doctorpemm)

How can you enhance outcomes for your pediatric patients with acute lymphoblastic #leukemia? Drs. Maese & Rau (@RachelRau3) discuss optimal strategies for asparaginase dosing, toxicity mitigation & hypersensitivity/infusion reactions in this CME/MOC video https://t.co/LiIV35UumE (@PeerView)